CA2486917C - Topically applicable pharmaceutical preparation containing roflumilast - Google Patents
Topically applicable pharmaceutical preparation containing roflumilast Download PDFInfo
- Publication number
- CA2486917C CA2486917C CA2486917A CA2486917A CA2486917C CA 2486917 C CA2486917 C CA 2486917C CA 2486917 A CA2486917 A CA 2486917A CA 2486917 A CA2486917 A CA 2486917A CA 2486917 C CA2486917 C CA 2486917C
- Authority
- CA
- Canada
- Prior art keywords
- roflumilast
- pharmaceutical preparation
- topically applicable
- disorders
- applicable pharmaceutical
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/08—Antiseborrheics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/16—Emollients or protectives, e.g. against radiation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/14—Decongestants or antiallergics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- F—MECHANICAL ENGINEERING; LIGHTING; HEATING; WEAPONS; BLASTING
- F41—WEAPONS
- F41B—WEAPONS FOR PROJECTING MISSILES WITHOUT USE OF EXPLOSIVE OR COMBUSTIBLE PROPELLANT CHARGE; WEAPONS NOT OTHERWISE PROVIDED FOR
- F41B5/00—Bows; Crossbows
- F41B5/12—Crossbows
-
- F—MECHANICAL ENGINEERING; LIGHTING; HEATING; WEAPONS; BLASTING
- F41—WEAPONS
- F41B—WEAPONS FOR PROJECTING MISSILES WITHOUT USE OF EXPLOSIVE OR COMBUSTIBLE PROPELLANT CHARGE; WEAPONS NOT OTHERWISE PROVIDED FOR
- F41B5/00—Bows; Crossbows
- F41B5/12—Crossbows
- F41B5/123—Compound crossbows
-
- F—MECHANICAL ENGINEERING; LIGHTING; HEATING; WEAPONS; BLASTING
- F41—WEAPONS
- F41B—WEAPONS FOR PROJECTING MISSILES WITHOUT USE OF EXPLOSIVE OR COMBUSTIBLE PROPELLANT CHARGE; WEAPONS NOT OTHERWISE PROVIDED FOR
- F41B5/00—Bows; Crossbows
- F41B5/14—Details of bows; Accessories for arc shooting
- F41B5/1442—Accessories for arc or bow shooting
- F41B5/1469—Bow-string drawing or releasing devices
Abstract
A topical pharmaceutical preparation for administering a slightly soluble PDE4 inhibitor (roflumilast) is describe. A surprisingly good systemic bioavailability is observed with this dosage form.
Description
TOPICALLY APPLICABLE PHARMACEUTICAL PREPARATION CONTAINING ROFLUMILAST
Technical field The present invention relates to the field of pharmaceutical technology and describes a topically applicable pharmaceutical preparation comprising as active ingredient a slightly soluble POE 4 inhibitor.
The invention additionally relates to processes for producing the topically applicable pharmaceutical preparation and to the use for the treatment of disorders of the skin, of the eyes and of the airways.
Prior art Cyclic nucleotide phosphodiesterase (PDE) Inhibitors (specifically of type 4) are currently of special interest as a new generation of active ingredients for treating inflammatory disorders, especially disor-ders of the airways such as asthma or airway obstructions (such as, for example, COPD -- chronic ob-structive pulmonary disease). A number of POE 4 Inhibitors are currently undergoing advanced clinical testing, including a dosage form for oral administration comprising the active ingredient N-(3,5-di-chioropyrid-4-y1)-3-cyclopropyimethoxy-4-difluoramethoxybenzamide (INN:
roflumilast). This and other compounds with a benzamide structure and their use as cyclic nucleotide phosphodiesterase (POE) inhibitors are described in WO 95/01338. These active ingredients are proposed in WO 95/01338 also for the treatment of certain disorders of the skin (such as, for example, derrnatoses). WO 00/53182 proposes the use of roflumilast or its N-oxide for the treatment of multiple sclerosis.
For treating disorders of the skin it is desirable to provide the active pharmaceutical ingredient in a pharmaceutical preparation suitable for topical application, As the skilled person is aware, however, the provision of dosage forms for topical application may prove to be extremely difficult or Is impossible if the intention is to administer an active Ingredient which has a very low solubility. Thus, for example, the solubility in water found for the PDE 4 inhibitor N-(3,5-dichloropyrid-4-yy-3-cyclopropylmethoxy-4-di-fluoromethoxybenzamide (INN: roflumilast), which is described in WO 95101338, is only 0.53 mg/1 at 21 C.
Description of the invention It has now been found, surprisingly, that topically applicable pharmaceutical preparations comprising the slightly soluble PDE 4 inhibitor roflumilast show a very good effect in the treatment of dermatoses an local, dermal application. Also found, entirely surprisingly, besides the local effect, is an excellent systemic effect which is comparable with that of an oral dosage form.
.2-A first aspect of the invention is therefore a pharmaceutical preparation which can be administered topically and comprises an active pharmaceutical ingredient together with one or more pharmaceutical carriers and/or excipients suitable for topical administration, the active pharmaceutical ingredient being a compound selected from the group consisting of roflumilast, salts of roflumilast, the N-oxide of ro-flumilast and salts thereof.
Roflumilast is the INN for a compound of the formula I
H
N,, R3 (1) in which RI is difluoromethoxy, R2 is cyclopropylmethoxy and R3 is 3,5-dichloropyrid-4-yl.
This compound has the chemical name N-(3,5-dichloropyrid-4-yl)-3-cyclopropylmethoxy-4-difluoro-methoxybenzamide (INN: roflumilast). The N-oxide of roflumilast has the chemical name 3-cyclo-propylmethoxy-4-difluoromethoxy-N-(3,5-dichloropyrid-4-yl 1-oxide)benzamide.
This compound of the formula I, its salts, the N-oxide, its salts and the use of these compounds as phosphodiesterase (PDE) 4 inhibitors are described in the international patent application WO 95/01338.
Salts suitable for compounds of the formula I - depending on the substitution -are all acid addition salts but, in particular, all salts with bases. Particular mention may be made of the pharmacologically acceptable salts of the inorganic and organic acids and bases normally used in pharmaceutical technology. Pharmacologically unacceptable salts which, for example, may be the initial products of the process for preparing the compounds of the invention on the industrial scale are converted into pharmacologically acceptable salts by processes known to the skilled worker.
Those suitable on the one hand are water-soluble and water-insoluble acid addition salts with acids such as, for example, hydrochloric acid, hydrobromic acid, phosphoric acid, nitric acid, sulfuric acid, acetic acid, citric acid, D-gluconic acid, benzoic acid, 2-(4-hydroxybenzoyl)benzoic acid, butyric acid, sulphosalicylic acid, maleic acid, lauric acid, malic acid, fumaric acid, succinic acid, oxalic acid, tartaric acid, embonic acid, stearic acid, toluenesulphonic acid, methanesulphonic acid, or 3-hydroxy-2-naphthoic acid, the acids being employed to prepare the salts in the equimolar ratio of amounts, or one differing therefrom -depending on whether the acid is monobasic or polybasic and depending on which salt is desired.
On the other hand, salts with bases are also particularly suitable. Examples of basic salts which may be mentioned are lithium, sodium, potassium, calcium, aluminium, magnesium, titanium, ammonium, me-glumine or guanidinium salts, once again the bases being employed to prepare the salts in the equimo-lar ratio of amounts or one differing therefrom.
The proportion (in per cent by weight based on the weight of the finished pharmaceutical preparation;
w/w) of active pharmaceutical ingredient in the pharmaceutical preparation of the invention is usually from 0.001 to 50% by weight. The proportion of active pharmaceutical ingredient is preferably up to 1 %
by weight.
The pharmaceutical carriers and/or excipients suitable for topical administration are preferably accord-ing to the invention conventional carriers and/or excipients known to the skilled person in connection with pharmaceutical preparations for dermal administration (=
dermatologicals). Examples which may be mentioned are carriers and/or excipients which are suitable for producing dusting powders, emul-sions, suspensions, sprays, oils, ointments, greasy ointments, creams, pastes, gels, foams or solutions, and transdermal therapeutic systems.
The topical pharmaceutical preparation of the invention can be produced by processes familiar to the skilled person.
Conventional dermatologicals and their production, and preferred carriers and/or excipients for the indi-vidual pharmaceutical preparations are described, for example, in the textbook "Pharmazeutische Technologie" (Sucker, Fuchs, Speiser, Georg Thieme Verlag,1978 from page 629).
In a first embodiment of the invention, the topical pharmaceutical preparation of the invention is a semi-solid dosage form. Examples which may be mentioned are, in particular, ointments (e.g. solution oint-ment, suspension ointment), creams, gels or pastes.
Oil-in-water or water-in-oil emulsions are normally referred to as creams.
Chiefly used for the oily phase are fatty alcohols, e.g. lauryl, cetyl or stearyl alcohol, fatty acids, e.g.
palmitic or stearic acid, liquid or solid paraffins or ozokerite, liquid to solid waxes, e.g. isopropyl myristate, natural or partially synthetic fat, e.g. coconut fatty acid triglyceride, hardened oils, e.g. hydrogenated peanut or castor oil, or fatty acid partial esters of glycerol, e.g. glycerol monostearate or glycerol distearate. Suitable emulsifiers are surface-active substances, e.g. nonionic surfactants, e.g. fatty acid esters of polyalcohols or ethylene oxide adducts thereof, such as polyglycerol fatty acid esters or polyoxyethylene sorbitan fatty acid es-ters (Tween : ICI,) sorbitan fatty acid esters (Span : ICI), such as, for example, sorbitan oleate and/or sorbitan isostearate, sterols, also polyoxyethylene fatty alcohol ethers or fatty acid esters, or anionic surfactants such as alkali metal salts of fatty alcohol sulphates, e.g. sodium lauryl sulphate, sodium cetyl sulphate or sodium stearyl sulphate, which are normally used in the presence of said fatty alco-hols, e.g. cetyl alcohol or stearyl alcohol. It is possible to add to the aqueous phase inter alia agents which prevent the cream drying out, e.g. polyalcohols such as glycerol, sorbitol, propylene glycol and/or polyethylene glycols, also preservatives, fragrances etc.
Ointments may be anhydrous and contain as base the paraffins which are suitable for topical use and are liquid at body temperature, especially low-viscosity paraffin, also the said natural or partially syn-thetic fats, e.g. coconut fatty acid triglyceride, hardened oils, e.g.
hydrogenated peanut or castor oil, fatty acid partial esters of glycerol, e.g. glycerol monostearate and distearate, silicones, e.g. polydi-methylsiloxanes, e.g. hexamethyldisiloxane or octamethyltrisiloxane, and, for example, the fatty alco-hols mentioned in connection with the hydrous creams and increasing the water uptake capacity, and sterols, wool waxes, other emulsifiers and/or other additives.
In the case of gels, a distinction is made between hydrous, anhydrous and low water-content gels, which consist of swellable, gel-forming material. Chiefly suitable are transparent hydrogels based on inorganic or organic macromolecules. Macromolecular inorganic components with gel-forming proper-ties are predominantly hydrous or water-absorbing silicates such as aluminium silicates, e.g. bentonite, magnesium-aluminium silicates, e.g. Veegum - Vanderbilt Exp. Corp., or colloidal silica, e.g. Aerosil - Degussa. Examples of macromolecular organic substances used are natural, semisynthetic or syn-thetic polymers. Natural and semisynthetic polymers are derived, for example, from polysaccharides with different carbohydrate units, such as cellulose, starch, tragacanth, gum arabic, agar-agar, gelatin, alginic acid and salts thereof, e.g. sodium alginate and derivatives thereof, lower alkylcellulose, for ex-ample methyl- or ethylcellulose, carboxy- or hydroxy-lower-alkylcellulose, e.g. carboxymethyl- or hy-droxypropylcellulose. The units of synthetic, gel-forming polymers are, for example, unsaturated, substi-tuted aliphatic compounds such as vinyl alcohol, vinylpyrrolidone, acrylic or methacrylic acid. Examples to be mentioned of such polymers are polyvinyl alcohol derivatives such as Polyviol - Wacker, polyvi-nylpyrrolidones, such as Kollidon - BASF or Polyplasdon - General Aniline, polyacrylates and poly-methacrylates, such as Rohagit S - Rohm and Haas. It is possible to add conventional additives such as preservatives or fragrances to the gels.
Pastes are creams or ointments with the constituents mentioned hereinbefore and secretion-absorbing dusting powder constituents such as metal oxides, e.g. titanium oxide or zinc oxide, also talc and/or aluminium silicates, which have the task of binding moisture or secretions.
In a preferred embodiment of the invention, the topical pharmaceutical preparation of the invention is a semisolid pharmaceutical preparation, with one of the excipients being polyethylene glycol, in particular polyethylene glycol 400.
In a further embodiment of the invention, the topical pharmaceutical preparation of the invention is a transdermal therapeutic system (TTS), for example a system as described in Pharmazeutische Tech-nologie: Moderne Arzneiformen, Wissenschaftliche Verlagsgesellschaft mbH
Stuttgart 1997, pages 81 et sec. TTSs are characterized in principle by a defined supply of medicinal substance to the skin, a total dose of the medicinal substance in the TTS, a total area and an area which is possibly different therefrom for release of the medicinal substance, a covering sheet (backing layer) which is imperme-able to the medicinal substance, a medicinal substance reservoir, a control element which controls the supply of medicinal substance to the skin, a (pressure-sensitive) adhesive layer and a detachable pro-tective layer. It is possible on occasions for more than one function to be fulfilled by one and the same element, e.g. reservoir, control and adhesive functions by a suitable adhesive matrix. From the view-point of pharmaceutical technology, TTSs are categorized according to the way the control function is achieved, that is to say how it controls the supply of medicinal substance to the skin. Examples which are mentioned here are TTSs with membrane permeation-controlled release (membrane moderated drug delivery), TTSs with matrix diffusion-controlled release and TTSs with microreservoir solution-controlled release.
TTSs with membrane permeation-controlled release are characterized by a polymer membrane com-posed of a PVA-VA copolymer (Chronomer ) which controls the permeation of the medicinal sub-stance from the reservoir into the skin. The medicinal substance is initially in the form of solid particles or as a dispersion or solution in the reservoir. The polymer membrane can be attached to the reservoir in various ways (extrusion, encapsulation, microencapsulation). TTSs with matrix diffusion-controlled release have a comparatively simpler structure. They contain no separate control element. The release of medicinal substance is controlled by a lipophilic or hydrophilic polymer matrix and/or the adhesive layer. It is possible to distinguish, according to the characteristics of the matrix, between TTSs with a matrix in gel form and TTSs which represent solid polymer laminates. The medicinal substance reser-voir is formed by the medicinal substance dissolved in the matrix (monolithic system) or a homogene-ous dispersion of solid medicinal substance particles. A matrix TTS can be produced by mixing the medicinal substance particles with a viscous liquid or semisolid polymer at room temperature, followed by crosslinking the polymer chains. A further possibility is also to mix the medicinal substance at ele-vated temperature with softened polymer (hot melt technique), or the two components (dissolved in an organic solvent) are mixed together and the solvent is then removed in vacuo (solvent evaporation).
Shaping is possible by pouring into suitable moulds, spreading with special devices (knives) or by ex-trusion. In the case of TTSs with microreservoir solution-controlled release (microsealed drug delivery, MDD principle), numerous microcompartments containing the active ingredient and 10-200 pm in size are embedded in a matrix which represents both reservoir and delivery-control element. Because of the matrix, these TTSs are actually assigned to the matrix systems. For production, the medicinal sub-stance is initially dispersed together with water and 40% polyethylene glycol 400 in isopropyl palmitate, which acts as permeation promoter. The resulting dispersion is incorporated by using a special high-energy dispersion technique into a viscous silicone elastomer which simultaneously undergoes catalytic polymerization. The medicinal substance-containing matrix can be shaped specifically by melt or extru-sion techniques before it is combined with the carrier in the manner already described. Depending on the physicochemical properties of the medicinal substances and the intended liberation, it is possible to cover the matrix with a layer of a biocompatible polymer in order thus to modify the mechanism and the rate of liberation.
In another embodiment of the invention, the topical pharmaceutical preparation of the invention is a dosage form for use on the eye (ophthalmologicals). Examples which may be mentioned in this connec-tion are eyebaths or eye lotions, eye inserts, eye ointments, eye sprays, eye drops, preparations for intraocular injection and eyelid ointments. In a preferred embodiment, the dosage form of the invention is an eye ointment or eye drops. Eye drops preferably comprise according to the invention aqueous or oily suspensions of the active ingredient. It is preferred in this connection for the particle size of the active ingredient employed to be 90% less than 10 pm.
Preferably used in the case of aqueous suspensions are suspension stabilizers such as, for example, substituted celluloses (e.g. methylcellulose, hydroxypropylmethylcellulose), polyvinyl alcohol, polyvi-nylpyrrolidone, in addition to preservatives (e.g. chlorocresol, phenylmercury compounds, phenyletha-nol, benzalkonium chloride or mixtures of individual components) and, where appropriate, sodium chlo-ride to adjust to isotonicity. Preferably employed according to the invention in the case of oily eye drops are castor oil, peanut oil or medium chain length triglycerides. It is possible in the case of eye ointments to use according to the invention ointment bases which have the following properties: sterility or ex-tremely low microbe content, non-irritating, good activity, good distribution of the active ingredient or its solution in the ointment, suppleness, rapid dispersion as fine film over the eyeball, good adhesion to the eye, good stability and low impairment of vision. Hydrocarbon- or cholesterol-containing bases will therefore preferably be employed according to the invention for eye ointments.
In the case of petrola-tum, liquid paraffin is preferably added for consistency reasons. To achieve good spreading, it is pre-ferred according to the invention to provide compositions of limited viscosity. The viscosity at 32 C is preferably below 1 000 mPa.s, and the yield point is preferably below 300 mPa.
In the case of suspen-sion ointments it is preferred according to the invention for 90% of the active ingredient particles to be below 10 pm, and no particles above 90 pm should occur. In the case of water/oil emulsion ointments, it is preferred according to the invention to add preservatives such as benzalkonium chloride, thiomersal or phenylethyl alcohol.
Examples Production of the dosage forms of the invention Example 1 550 grams contain Polyethylene glycol 400 440.00 g Carbopol 9340 8.25 g Roflumilast 1.375 g Sodium hydroxide solution q.s.
Purified water to 550.00 g Production takes place by dissolving the active ingredient in the stated amount of polyethylene glycol at about 60-70 C. About 90 grams of purified water are added and mixed homogeneously, and the Car-bopol 934 is homogeneously dispersed therein with a high-speed stirrer. While stirring slowly, sodium hydroxide solution is added until a pH of 6.5-7.5 is reached. The remaining water is added up to the final weight and homogeneously mixed.
Example 2 550 grams contain Roflumilast 1.65 g Polyethylene glycol 400 440.00 g Polyethylene glycol 4000 to 550.0 g Production takes place by treating the two polyethylene glycols to 70 C to give a clear melt. The active ingredient is added likewise to give a clear solution. The preparation is cooled to room temperature while stirring slowly.
Example 3 550 grams contain Roflumilast 1.10 g Tego Care 150 27.50 g (Th. Goldschmidt) Neutral oil (Miglyol 812 ) 137.50 g Polyethylene glycol 400 275.00 g Cetostearyl alcohol 11.00 g Purified water to 550 g Production takes place by making a clear solution of the neutral oil, the cetostearyl alcohol and Tego Care 150 at about 70 C. The polyethylene glycol, in which the roflumilast has been dissolved, is like-wise stirred in using a high-speed stirrer. The water heated to 70 C is added to the lipid phase. A Tur-rax is used for homogenization. The preparation is then stirred until cold (room temperature).
Example 4 100 grams contain Roflumilast 0.25 g Neutral oil (Miglyol 812 ) 16.00 g Glycerol monostearate 8.00 g Cremophor A6 (BASF) 4.00 g Polyethylene glycol 400 62.50 g Purified water to 100.00 g Production takes place by heating all the components (apart from water) together to about 70-80 C to give a clear solution. The water is then added while stirring, and the preparation produced in this way is cooled to room temperature while stirring.
Example 5 100 grams contain Roflumilast 0.25 g Liquid paraffin 15.00 g Wool wax 5.00 g White petrolatum to 100 g Production takes place by making a clear melt of the liquid paraffin, the wool wax and the white petrola-tum at about 80 C. The micronized active ingredient is added, and the preparation is stirred until it has cooled to room temperature.
Example 6 Roflumilast 0.10 g Liquid paraffin 10.00 g Wool wax 5.00 g White petrolatum to 100 g Production takes place in analogy to Example 5.
Example 7 Roflumilast 0.10 g Neutral oil (Miglyol 812 ) 16.00 g Glycerol monostearate 8.00 g Cremophor A6 (BASF) 2.00 g Polyethylene glycol 400 62.50 g Purified water to 100.00 g Production takes place in analogy to Example 4.
Example 8 Roflumilast 0.10 g Neutral oil ( Miglyol 812 ) 16.00 g Glycerol monostearate 8.00 g Cremophor A6 (BASF) 4.00 g Polyethylene glycol 400 62.50 g Purified water to 100.00 g Production takes place in analogy to Example 4.
Example 9 Composition of an eye ointment (quantity for 1 000 grams) Roflumilast 1 g Cetyl alcohol 4 g High-viscosity paraffin 200 g White petrolatum 795 g WO 03/099334 - .10- PCT/EP03/05524 Production: A clear melt of the cetyl alcohol, the high-viscosity paraffin and the white petrolatum is pre-pared at about 70 C. The micronized roflumilast (90% of the particles below 10 pm) is stirred in, and a homogeneous dispersion is prepared using an Ultra-Turrax. The suspension is cooled to room tem-perature while stirring and used to fill suitable tubes.
Example 10 Composition of a drop solution in the form of an emulsion (quantity for 1 000 millilitres) Roflumilast 1.5 g Medium chain length triglycerides 100.0 g Lecithin 12.0 g Glycerol 25.0 g Thiomersal 0.1 g Purified water to 1 000 ml Production: First the roflumilast and then the lecithin are dissolved in the medium chain length triglyc-erides and the glycerol at 30 C-40 C. While stirring vigorously, the purified water is added and then homogenized until the droplet size of the disperse phase is below 500 nm. The thiomersal is dissolved by stirring. The emulsion is filtered through a 0.45 pm filter and dispensed into suitable containers.
Example 11 Composition of a nose ointment (quantity for 1 000 grams) Roflumilast 1 g Cetyl alcohol 4 g Wool wax 50 g High-viscosity paraffin 200 g White petrolatum 745 g Production: A clear melt of the cetyl alcohol, the high-viscosity paraffin, the wool wax and the white petrolatum is prepared at about 70 C. The micronized roflumilast (90% of the particles below 10pm) is stirred in, and a homogeneous dispersion is prepared using an Ultra-Turrax.
The suspension is cooled to room temperature while stirring and used to fill suitable tubes.
Investigations of the pharmacokinetics of the topical pharmaceutical preparations Comparison of pharmacokinetics parameters of topical pharmaceutical preparations of the in-vention with oral form Example A
A preparation corresponding to Example 7 and a preparation corresponding to Example 8 containing [14C]roflumilast were applied to shaven areas of rat skin (5 male Wistar rats) 4 cm2 in size. The radioac-tivity concentrations were measured in the plasma after I h, 4 h, 8 h, 24 h and in the urine (0-24 h) (n = 5). The dose was 1.7 mg/kg.
Results:
Preparation of Example 7: Cmax: 0.214 mg equiv./l, AUC(0-24 h): 4.13 (mg equiv./I x h) Preparation of Example 8: Cmax: 0.214 mg equiv./l, AUC(0-24 h): 3.99 (mg equiv./I x h) The results standardized to 1 mg/kg are Preparation of Example 7: Cmax: 0.126, AUC: 2.43 Preparation of Example 8: Cmax: 0.126, AUC: 2.35 Comparison with kinetic parameters after oral administration of 1 mg/kg:
Cmax: 0.225 mg equiv./l, AUC(0-24 h): 3.10 (mg equiv./I x h) The ratio of the AUC (preparation of Example 7) to the AUC (oral) is 78% and that of the AUG (prepara-tion of Example 8) to the AUG (oral) is 76%.
Results of comparison of the excretions with the urine:
Preparation of Example 7: 19.4% of the dose Preparation of Example 8: 18.0% of the dose Oral administration: 18.4% of the dose Conclusion:
After percutaneous administration of 1.7 mg/kg [14C]roflumilast to rats, the total radioactivity is trans-ported well through the skin and reaches a maximum plasma level of 0.214 mg equiv./I after 4 h, irre-spective of the preparation employed. Based on the total radioactivity, the AUCs and the excretions with the urine after percutaneous administration are negligibly different from those after oral administration.
- WO 03/099334 -12- PCT/EP03/05524 Example B
A preparation corresponding to Example 5 containing [14C]roflumilast was applied to a shaven area of rat skin (male Wistar rat) 4 cm2 in size. The radioactivity concentrations were measured in the plasma after 1 h, 4 h, 8 h, 24 h and in the urine (0-24 h) (n = 5). The dose was 1.77 mg/kg.
Preparation of Example 5: Cmax: 0.331 mg equiv./l, AUC(0-24 h): 4.99 (mg equiv./I x h) The results standardized to 1 mg/kg are Preparation of Example 5: Cmax: 0.187, AUC: 2.82 Comparison with kinetic parameters after oral administration of 1 mg/kg:
Cmax: 0.225 mg equiv./l, AUC(0-24 h): 3.10 (mg equiv./I x h) Results of comparison of the excretions with the urine:
Preparation of Example 5: 22.0% of the. dose Oral administration: 18.4% of the dose Conclusion:
These data show that roflumilast is absorbed from the preparation of Example 5 even somewhat better than from the preparations corresponding to Example 7 or 8. The excretion with the urine in the 24 h after administration is 22%, which is also in the region of the excretion with the urine after dermal ad-ministration of the preparations corresponding to Example 7 or 8. Comparison with oral administration shows that, irrespective of the composition of the topical preparation, similar Cmax and AUCs and simi-lar excretions with the urine are achieved.
WO 03/099334 -13- PCT/EP03/05524 Industrial applicability The dosage forms of the invention can be employed for the treatment and prevention of all diseases regarded as treatable or preventable through the use of PDE 4 inhibitors.
Selective cyclic nucleotide phosphodiesterase (PDE) inhibitors (specifically of type 4) are suitable on the one hand as bronchial therapeutic agents (for the treatment of airway obstructions owing to their dilating effect but also owing to their effect increasing the respiratory rate and respiratory drive) and for eliminating erectile dysfunc-tion owing to the vasodilating effect, but on the other hand especially for the treatment of disorders, especially of an inflammatory nature, e.g. of the airways (asthma prophylaxis), of the skin, of the central nervous system, of the intestine, of the eyes and of the joints, which are promoted by mediators such as histamine, PAF (platelet-activating factor), arachidonic acid derivatives such as leukotrienes and prostaglandins, cytokines, interleukins, chemokines, alpha-, beta- and gamma-interferon, tumor necro-sis factor (TNF) or oxygen free radicals and proteases. The pharmaceutical preparations of the inven-tion can therefore be used in human and veterinary medicine for example for the treatment and prophy-laxis of the following diseases: acute and chronic (especially inflammatory and allergen-induced) airway disorders of various aetiologies (bronchitis, allergic bronchitis, bronchial asthma, COPD); dermatoses (especially of a proliferative, inflammatory and allergic nature) such as, for example, psoriasis (vul-garis), toxic and allergic contact eczema, atopic eczema, seborrhoeic eczema, lichen simplex, sunburn, pruritus in the genitoanal region, alopecia areata, hypertrophic scars, discoid lupus erythematosus, follicular and extensive pyodermas, endogenous and exogenous acne, acne rosacea and other prolif-erative, inflammatory and allergic skin disorders; disorders based on excessive release of TNF and leukotrienes, e.g. disorders of the arthritic type (rheumatoid arthritis, rheumatoid spondylitis, osteoarthri-tis and other arthritic states), disorders of the immune system (AIDS, multiple sclerosis), types of shock [septic shock, endotoxin shock, gram-negative sepsis, toxic shock syndrome and ARDS (adult respira-tory distress syndrome)] and generalized inflammations in the gastrointestinal region (Crohn's disease and ulcerative colitis); disorders based on allergic and/or chronic abnormal immunological reactions in the region of the upper airways (pharyngeal space, nose) and adjacent regions (paranasal sinuses, eyes), such as, for example, allergic rhinitis/sinusitis, chronic rhinitis/sinusitis, allergic conjunctivitis, conjunctivitis caused by bacteria, viruses or fungi, inflammatory states after intraocular lens implanta-tion, inflammation of the optic nerve (neuritis nervi optici), keratitis, dry eye syndrome (keratitis sicca), uveitis, glaucoma, retinal oedema, retinitis pigmentosa, diabetic retinopathy, and nasal polyps; but also cardiac disorders which can be treated by PDE inhibitors, such as, for example, heart failure, or disor-ders which can be treated owing to the tissue-relaxant effect of PDE
inhibitors, such as, for example, erectile dysfunction or colic of the kidneys and ureters connected with kidney stones; or else disorders of the CNS such as, for example, depressions or arteriosclerotic dementia.
The pharmaceutical preparations of the invention are particularly suitable for the treatment of disorders of the skin such as dermatoses (especially of a proliferative, inflammatory and allergic nature) such as, for example, psoriasis (vulgaris), toxic and allergic contact eczema, atopic eczema, seborrhoeic ec-zema, lichen simplex, sunburn, pruritus in the genitoanal region, alopecia areata, hypertrophic scars, WO 03/099334 -14- PCT/EP03/05524 discoid lupus erythematosus, follicular and extensive pyodermas, endogenous and exogenous acne, acne rosacea and other proliferative, inflammatory and allergic skin disorders. Mention may preferably be made of the use of the pharmaceutical preparations of the invention in the treatment of psoriasis and atopic eczema.
The invention therefore also relates further to the use of roflumilast, salts of roflumilast, the N-oxide of roflumilast or salts thereof for producing a topical pharmaceutical preparation for dermal administration for the treatment of disorders of the skin which are regarded as treatable or preventable by application of PDE 4 inhibitors. Mention may preferably be made in this connection of dermatoses (especially of a proliferative, inflammatory and allergic nature) such as, for example, psoriasis (vulgaris), toxic and al-lergic contact eczema, atopic eczema, seborrhoeic eczema, lichen simplex, sunburn, pruritus in the genitoanal region, alopecia areata, hypertrophic scars, discoid lupus erythematosus, follicular and ex-tensive pyodermas, endogenous and exogenous acne, acne rosacea and other proliferative, inflamma-tory and allergic skin disorders.
The invention further relates to a method for the treatment of mammals, including humans, suffering from one of the abovementioned diseases. The method is characterized in that a therapeutically effec-tive and pharmacologically suitable amount of an active pharmaceutical ingredient selected from the group of compounds roflumilast, salts of roflumilast, the N-oxide of roflumilast and salts thereof is ad-ministered to the mammal with the disease, with the active pharmaceutical ingredient being adminis-tered in a topical pharmaceutical preparation of the invention. The disease is preferably a disorder of the skin such as dermatoses (especially of a proliferative, inflammatory and allergic nature) such as, for example, psoriasis (vulgaris), toxic and allergic contact eczema, atopic eczema, seborrhoeic eczema, lichen simplex, sunburn, pruritus in the genitoanal region, alopecia areata, hypertrophic scars, discoid lupus erythematosus, follicular and extensive pyodermas, endogenous and exogenous acne, acne rosacea and other proliferative, inflammatory and allergic skin disorders. The method is characterized in that the administration takes place by dermal administration, i.e. through application of the topical pharmaceutical preparations of the invention to the skin or mucous membranes.
In another preferred embodiment, the invention relates to the treatment of mammals, including humans, suffering from an eye disorder which is regarded as treatable or preventable through the use of PDE4 inhibitors. This eye disorder is preferably selected from the group of allergic conjunctivitis, conjunctivitis caused by bacteria, viruses or fungi, inflammatory states after intraocular lens implantation, inflamma-tion of the optic nerve (neuritis nervi optici), keratitis, dry eye syndrome (keratitis sicca), uveitis, glau-coma, retinal oedema, retinitis pigmentosa and diabetic retinopathy. The eye disorder is preferably al-lergic conjunctivitis, conjunctivitis caused by bacteria, viruses or fungi, inflammatory states after in-traocular lens implantation or uveitis. The method is characterized in that the administration takes place by application of the preparation of the invention to the eye.
The good systemic availability surprisingly observed on topical administration makes the pharmaceuti-WO 03/099334 -15- PCT/EP03/05524 cal preparations of the invention additionally suitable for systemic treatment and thus for the treatment of all other diseases which are regarded as treatable or preventable through application of PDE 4 inhibi-tors, especially the abovementioned diseases.
The invention therefore also relates further to the use of roflumilast, salts of roflumilast, the N-oxide of roflumilast or salts thereof for producing a topical pharmaceutical preparation for dermal administration for the systemic treatment of diseases regarded as treatable or preventable by application of PDE 4 inhibitors. Mention may preferably be made in this connection of acute and chronic (especially inflam-matory and allergen-induced) airway disorders of various aetiologies (bronchitis, allergic bronchitis, bronchial asthma, COPD), and disorders of the arthritic type (rheumatoid arthritis, rheumatoid spondy-litis, osteoarthritis and other arthritic states).
The pharmaceutical preparations of the invention are moreover particularly suitable for adminstration to groups of patients who are suffering from the abovementioned diseases and have problems in taking pharmaceutical preparations to be administered orally, such as, for example, bedridden patients, pa-tients in intensive medical care, patients with swallowing difficulties and children.
The invention further relates to a method for the treatment of mammals, including humans, suffering from one of the abovementioned diseases. The method is characterized in that a therapeutically effec-tive and pharmacologically suitable amount of an active pharmaceutical ingredient selected from the group of compounds roflumilast, salts of roflumilast, the N-oxide of roflumilast and salts thereof is ad-ministered to the mammal with the disease, with the active pharmaceutical ingredient being adminis-tered in a topical pharmaceutical preparation of the invention. The disease is preferably acute and chronic (especially inflammatory and allergen-induced) airway disorders of various aetiologies (bronchi-tis, allergic bronchitis, bronchial asthma, COPD), and disorders of the arthritic type (rheumatoid arthritis, rheumatoid spondylitis, osteoarthritis and other arthritic states). The method is characterized in that administration takes place by dermal administration, i.e. through application of the topical pharmaceuti-cal preparations of the invention to the skin or mucous membranes.
The dosage forms of the invention comprise the active pharmaceutical ingredient in the dose customary for the treatment of the particular disease. The dosage of the active ingredient is of the order of magni-tude customary for PDE inhibitors, it being possible to administer the daily dose in one or more dosage units. Customary dosages are disclosed for example in WO 95/01338. The normal dose on systemic therapy (oral) is between 0.001 and 3 mg per kilogram and day. Dosage forms preferred according to the invention for topical administration contain from 0.005 mg to 5 mg of roflumilast, preferably from 0.01 mg to 2.5 mg, particularly preferably 0.1 mg to 0.5 mg of roflumilast per dosage unit. Examples of pharmaceutical preparations of the invention contain 0.01 mg, 0.1 mg, 0.125 mg, 0.25 mg and 0.5 mg of roflumilast per dosage unit.
Technical field The present invention relates to the field of pharmaceutical technology and describes a topically applicable pharmaceutical preparation comprising as active ingredient a slightly soluble POE 4 inhibitor.
The invention additionally relates to processes for producing the topically applicable pharmaceutical preparation and to the use for the treatment of disorders of the skin, of the eyes and of the airways.
Prior art Cyclic nucleotide phosphodiesterase (PDE) Inhibitors (specifically of type 4) are currently of special interest as a new generation of active ingredients for treating inflammatory disorders, especially disor-ders of the airways such as asthma or airway obstructions (such as, for example, COPD -- chronic ob-structive pulmonary disease). A number of POE 4 Inhibitors are currently undergoing advanced clinical testing, including a dosage form for oral administration comprising the active ingredient N-(3,5-di-chioropyrid-4-y1)-3-cyclopropyimethoxy-4-difluoramethoxybenzamide (INN:
roflumilast). This and other compounds with a benzamide structure and their use as cyclic nucleotide phosphodiesterase (POE) inhibitors are described in WO 95/01338. These active ingredients are proposed in WO 95/01338 also for the treatment of certain disorders of the skin (such as, for example, derrnatoses). WO 00/53182 proposes the use of roflumilast or its N-oxide for the treatment of multiple sclerosis.
For treating disorders of the skin it is desirable to provide the active pharmaceutical ingredient in a pharmaceutical preparation suitable for topical application, As the skilled person is aware, however, the provision of dosage forms for topical application may prove to be extremely difficult or Is impossible if the intention is to administer an active Ingredient which has a very low solubility. Thus, for example, the solubility in water found for the PDE 4 inhibitor N-(3,5-dichloropyrid-4-yy-3-cyclopropylmethoxy-4-di-fluoromethoxybenzamide (INN: roflumilast), which is described in WO 95101338, is only 0.53 mg/1 at 21 C.
Description of the invention It has now been found, surprisingly, that topically applicable pharmaceutical preparations comprising the slightly soluble PDE 4 inhibitor roflumilast show a very good effect in the treatment of dermatoses an local, dermal application. Also found, entirely surprisingly, besides the local effect, is an excellent systemic effect which is comparable with that of an oral dosage form.
.2-A first aspect of the invention is therefore a pharmaceutical preparation which can be administered topically and comprises an active pharmaceutical ingredient together with one or more pharmaceutical carriers and/or excipients suitable for topical administration, the active pharmaceutical ingredient being a compound selected from the group consisting of roflumilast, salts of roflumilast, the N-oxide of ro-flumilast and salts thereof.
Roflumilast is the INN for a compound of the formula I
H
N,, R3 (1) in which RI is difluoromethoxy, R2 is cyclopropylmethoxy and R3 is 3,5-dichloropyrid-4-yl.
This compound has the chemical name N-(3,5-dichloropyrid-4-yl)-3-cyclopropylmethoxy-4-difluoro-methoxybenzamide (INN: roflumilast). The N-oxide of roflumilast has the chemical name 3-cyclo-propylmethoxy-4-difluoromethoxy-N-(3,5-dichloropyrid-4-yl 1-oxide)benzamide.
This compound of the formula I, its salts, the N-oxide, its salts and the use of these compounds as phosphodiesterase (PDE) 4 inhibitors are described in the international patent application WO 95/01338.
Salts suitable for compounds of the formula I - depending on the substitution -are all acid addition salts but, in particular, all salts with bases. Particular mention may be made of the pharmacologically acceptable salts of the inorganic and organic acids and bases normally used in pharmaceutical technology. Pharmacologically unacceptable salts which, for example, may be the initial products of the process for preparing the compounds of the invention on the industrial scale are converted into pharmacologically acceptable salts by processes known to the skilled worker.
Those suitable on the one hand are water-soluble and water-insoluble acid addition salts with acids such as, for example, hydrochloric acid, hydrobromic acid, phosphoric acid, nitric acid, sulfuric acid, acetic acid, citric acid, D-gluconic acid, benzoic acid, 2-(4-hydroxybenzoyl)benzoic acid, butyric acid, sulphosalicylic acid, maleic acid, lauric acid, malic acid, fumaric acid, succinic acid, oxalic acid, tartaric acid, embonic acid, stearic acid, toluenesulphonic acid, methanesulphonic acid, or 3-hydroxy-2-naphthoic acid, the acids being employed to prepare the salts in the equimolar ratio of amounts, or one differing therefrom -depending on whether the acid is monobasic or polybasic and depending on which salt is desired.
On the other hand, salts with bases are also particularly suitable. Examples of basic salts which may be mentioned are lithium, sodium, potassium, calcium, aluminium, magnesium, titanium, ammonium, me-glumine or guanidinium salts, once again the bases being employed to prepare the salts in the equimo-lar ratio of amounts or one differing therefrom.
The proportion (in per cent by weight based on the weight of the finished pharmaceutical preparation;
w/w) of active pharmaceutical ingredient in the pharmaceutical preparation of the invention is usually from 0.001 to 50% by weight. The proportion of active pharmaceutical ingredient is preferably up to 1 %
by weight.
The pharmaceutical carriers and/or excipients suitable for topical administration are preferably accord-ing to the invention conventional carriers and/or excipients known to the skilled person in connection with pharmaceutical preparations for dermal administration (=
dermatologicals). Examples which may be mentioned are carriers and/or excipients which are suitable for producing dusting powders, emul-sions, suspensions, sprays, oils, ointments, greasy ointments, creams, pastes, gels, foams or solutions, and transdermal therapeutic systems.
The topical pharmaceutical preparation of the invention can be produced by processes familiar to the skilled person.
Conventional dermatologicals and their production, and preferred carriers and/or excipients for the indi-vidual pharmaceutical preparations are described, for example, in the textbook "Pharmazeutische Technologie" (Sucker, Fuchs, Speiser, Georg Thieme Verlag,1978 from page 629).
In a first embodiment of the invention, the topical pharmaceutical preparation of the invention is a semi-solid dosage form. Examples which may be mentioned are, in particular, ointments (e.g. solution oint-ment, suspension ointment), creams, gels or pastes.
Oil-in-water or water-in-oil emulsions are normally referred to as creams.
Chiefly used for the oily phase are fatty alcohols, e.g. lauryl, cetyl or stearyl alcohol, fatty acids, e.g.
palmitic or stearic acid, liquid or solid paraffins or ozokerite, liquid to solid waxes, e.g. isopropyl myristate, natural or partially synthetic fat, e.g. coconut fatty acid triglyceride, hardened oils, e.g. hydrogenated peanut or castor oil, or fatty acid partial esters of glycerol, e.g. glycerol monostearate or glycerol distearate. Suitable emulsifiers are surface-active substances, e.g. nonionic surfactants, e.g. fatty acid esters of polyalcohols or ethylene oxide adducts thereof, such as polyglycerol fatty acid esters or polyoxyethylene sorbitan fatty acid es-ters (Tween : ICI,) sorbitan fatty acid esters (Span : ICI), such as, for example, sorbitan oleate and/or sorbitan isostearate, sterols, also polyoxyethylene fatty alcohol ethers or fatty acid esters, or anionic surfactants such as alkali metal salts of fatty alcohol sulphates, e.g. sodium lauryl sulphate, sodium cetyl sulphate or sodium stearyl sulphate, which are normally used in the presence of said fatty alco-hols, e.g. cetyl alcohol or stearyl alcohol. It is possible to add to the aqueous phase inter alia agents which prevent the cream drying out, e.g. polyalcohols such as glycerol, sorbitol, propylene glycol and/or polyethylene glycols, also preservatives, fragrances etc.
Ointments may be anhydrous and contain as base the paraffins which are suitable for topical use and are liquid at body temperature, especially low-viscosity paraffin, also the said natural or partially syn-thetic fats, e.g. coconut fatty acid triglyceride, hardened oils, e.g.
hydrogenated peanut or castor oil, fatty acid partial esters of glycerol, e.g. glycerol monostearate and distearate, silicones, e.g. polydi-methylsiloxanes, e.g. hexamethyldisiloxane or octamethyltrisiloxane, and, for example, the fatty alco-hols mentioned in connection with the hydrous creams and increasing the water uptake capacity, and sterols, wool waxes, other emulsifiers and/or other additives.
In the case of gels, a distinction is made between hydrous, anhydrous and low water-content gels, which consist of swellable, gel-forming material. Chiefly suitable are transparent hydrogels based on inorganic or organic macromolecules. Macromolecular inorganic components with gel-forming proper-ties are predominantly hydrous or water-absorbing silicates such as aluminium silicates, e.g. bentonite, magnesium-aluminium silicates, e.g. Veegum - Vanderbilt Exp. Corp., or colloidal silica, e.g. Aerosil - Degussa. Examples of macromolecular organic substances used are natural, semisynthetic or syn-thetic polymers. Natural and semisynthetic polymers are derived, for example, from polysaccharides with different carbohydrate units, such as cellulose, starch, tragacanth, gum arabic, agar-agar, gelatin, alginic acid and salts thereof, e.g. sodium alginate and derivatives thereof, lower alkylcellulose, for ex-ample methyl- or ethylcellulose, carboxy- or hydroxy-lower-alkylcellulose, e.g. carboxymethyl- or hy-droxypropylcellulose. The units of synthetic, gel-forming polymers are, for example, unsaturated, substi-tuted aliphatic compounds such as vinyl alcohol, vinylpyrrolidone, acrylic or methacrylic acid. Examples to be mentioned of such polymers are polyvinyl alcohol derivatives such as Polyviol - Wacker, polyvi-nylpyrrolidones, such as Kollidon - BASF or Polyplasdon - General Aniline, polyacrylates and poly-methacrylates, such as Rohagit S - Rohm and Haas. It is possible to add conventional additives such as preservatives or fragrances to the gels.
Pastes are creams or ointments with the constituents mentioned hereinbefore and secretion-absorbing dusting powder constituents such as metal oxides, e.g. titanium oxide or zinc oxide, also talc and/or aluminium silicates, which have the task of binding moisture or secretions.
In a preferred embodiment of the invention, the topical pharmaceutical preparation of the invention is a semisolid pharmaceutical preparation, with one of the excipients being polyethylene glycol, in particular polyethylene glycol 400.
In a further embodiment of the invention, the topical pharmaceutical preparation of the invention is a transdermal therapeutic system (TTS), for example a system as described in Pharmazeutische Tech-nologie: Moderne Arzneiformen, Wissenschaftliche Verlagsgesellschaft mbH
Stuttgart 1997, pages 81 et sec. TTSs are characterized in principle by a defined supply of medicinal substance to the skin, a total dose of the medicinal substance in the TTS, a total area and an area which is possibly different therefrom for release of the medicinal substance, a covering sheet (backing layer) which is imperme-able to the medicinal substance, a medicinal substance reservoir, a control element which controls the supply of medicinal substance to the skin, a (pressure-sensitive) adhesive layer and a detachable pro-tective layer. It is possible on occasions for more than one function to be fulfilled by one and the same element, e.g. reservoir, control and adhesive functions by a suitable adhesive matrix. From the view-point of pharmaceutical technology, TTSs are categorized according to the way the control function is achieved, that is to say how it controls the supply of medicinal substance to the skin. Examples which are mentioned here are TTSs with membrane permeation-controlled release (membrane moderated drug delivery), TTSs with matrix diffusion-controlled release and TTSs with microreservoir solution-controlled release.
TTSs with membrane permeation-controlled release are characterized by a polymer membrane com-posed of a PVA-VA copolymer (Chronomer ) which controls the permeation of the medicinal sub-stance from the reservoir into the skin. The medicinal substance is initially in the form of solid particles or as a dispersion or solution in the reservoir. The polymer membrane can be attached to the reservoir in various ways (extrusion, encapsulation, microencapsulation). TTSs with matrix diffusion-controlled release have a comparatively simpler structure. They contain no separate control element. The release of medicinal substance is controlled by a lipophilic or hydrophilic polymer matrix and/or the adhesive layer. It is possible to distinguish, according to the characteristics of the matrix, between TTSs with a matrix in gel form and TTSs which represent solid polymer laminates. The medicinal substance reser-voir is formed by the medicinal substance dissolved in the matrix (monolithic system) or a homogene-ous dispersion of solid medicinal substance particles. A matrix TTS can be produced by mixing the medicinal substance particles with a viscous liquid or semisolid polymer at room temperature, followed by crosslinking the polymer chains. A further possibility is also to mix the medicinal substance at ele-vated temperature with softened polymer (hot melt technique), or the two components (dissolved in an organic solvent) are mixed together and the solvent is then removed in vacuo (solvent evaporation).
Shaping is possible by pouring into suitable moulds, spreading with special devices (knives) or by ex-trusion. In the case of TTSs with microreservoir solution-controlled release (microsealed drug delivery, MDD principle), numerous microcompartments containing the active ingredient and 10-200 pm in size are embedded in a matrix which represents both reservoir and delivery-control element. Because of the matrix, these TTSs are actually assigned to the matrix systems. For production, the medicinal sub-stance is initially dispersed together with water and 40% polyethylene glycol 400 in isopropyl palmitate, which acts as permeation promoter. The resulting dispersion is incorporated by using a special high-energy dispersion technique into a viscous silicone elastomer which simultaneously undergoes catalytic polymerization. The medicinal substance-containing matrix can be shaped specifically by melt or extru-sion techniques before it is combined with the carrier in the manner already described. Depending on the physicochemical properties of the medicinal substances and the intended liberation, it is possible to cover the matrix with a layer of a biocompatible polymer in order thus to modify the mechanism and the rate of liberation.
In another embodiment of the invention, the topical pharmaceutical preparation of the invention is a dosage form for use on the eye (ophthalmologicals). Examples which may be mentioned in this connec-tion are eyebaths or eye lotions, eye inserts, eye ointments, eye sprays, eye drops, preparations for intraocular injection and eyelid ointments. In a preferred embodiment, the dosage form of the invention is an eye ointment or eye drops. Eye drops preferably comprise according to the invention aqueous or oily suspensions of the active ingredient. It is preferred in this connection for the particle size of the active ingredient employed to be 90% less than 10 pm.
Preferably used in the case of aqueous suspensions are suspension stabilizers such as, for example, substituted celluloses (e.g. methylcellulose, hydroxypropylmethylcellulose), polyvinyl alcohol, polyvi-nylpyrrolidone, in addition to preservatives (e.g. chlorocresol, phenylmercury compounds, phenyletha-nol, benzalkonium chloride or mixtures of individual components) and, where appropriate, sodium chlo-ride to adjust to isotonicity. Preferably employed according to the invention in the case of oily eye drops are castor oil, peanut oil or medium chain length triglycerides. It is possible in the case of eye ointments to use according to the invention ointment bases which have the following properties: sterility or ex-tremely low microbe content, non-irritating, good activity, good distribution of the active ingredient or its solution in the ointment, suppleness, rapid dispersion as fine film over the eyeball, good adhesion to the eye, good stability and low impairment of vision. Hydrocarbon- or cholesterol-containing bases will therefore preferably be employed according to the invention for eye ointments.
In the case of petrola-tum, liquid paraffin is preferably added for consistency reasons. To achieve good spreading, it is pre-ferred according to the invention to provide compositions of limited viscosity. The viscosity at 32 C is preferably below 1 000 mPa.s, and the yield point is preferably below 300 mPa.
In the case of suspen-sion ointments it is preferred according to the invention for 90% of the active ingredient particles to be below 10 pm, and no particles above 90 pm should occur. In the case of water/oil emulsion ointments, it is preferred according to the invention to add preservatives such as benzalkonium chloride, thiomersal or phenylethyl alcohol.
Examples Production of the dosage forms of the invention Example 1 550 grams contain Polyethylene glycol 400 440.00 g Carbopol 9340 8.25 g Roflumilast 1.375 g Sodium hydroxide solution q.s.
Purified water to 550.00 g Production takes place by dissolving the active ingredient in the stated amount of polyethylene glycol at about 60-70 C. About 90 grams of purified water are added and mixed homogeneously, and the Car-bopol 934 is homogeneously dispersed therein with a high-speed stirrer. While stirring slowly, sodium hydroxide solution is added until a pH of 6.5-7.5 is reached. The remaining water is added up to the final weight and homogeneously mixed.
Example 2 550 grams contain Roflumilast 1.65 g Polyethylene glycol 400 440.00 g Polyethylene glycol 4000 to 550.0 g Production takes place by treating the two polyethylene glycols to 70 C to give a clear melt. The active ingredient is added likewise to give a clear solution. The preparation is cooled to room temperature while stirring slowly.
Example 3 550 grams contain Roflumilast 1.10 g Tego Care 150 27.50 g (Th. Goldschmidt) Neutral oil (Miglyol 812 ) 137.50 g Polyethylene glycol 400 275.00 g Cetostearyl alcohol 11.00 g Purified water to 550 g Production takes place by making a clear solution of the neutral oil, the cetostearyl alcohol and Tego Care 150 at about 70 C. The polyethylene glycol, in which the roflumilast has been dissolved, is like-wise stirred in using a high-speed stirrer. The water heated to 70 C is added to the lipid phase. A Tur-rax is used for homogenization. The preparation is then stirred until cold (room temperature).
Example 4 100 grams contain Roflumilast 0.25 g Neutral oil (Miglyol 812 ) 16.00 g Glycerol monostearate 8.00 g Cremophor A6 (BASF) 4.00 g Polyethylene glycol 400 62.50 g Purified water to 100.00 g Production takes place by heating all the components (apart from water) together to about 70-80 C to give a clear solution. The water is then added while stirring, and the preparation produced in this way is cooled to room temperature while stirring.
Example 5 100 grams contain Roflumilast 0.25 g Liquid paraffin 15.00 g Wool wax 5.00 g White petrolatum to 100 g Production takes place by making a clear melt of the liquid paraffin, the wool wax and the white petrola-tum at about 80 C. The micronized active ingredient is added, and the preparation is stirred until it has cooled to room temperature.
Example 6 Roflumilast 0.10 g Liquid paraffin 10.00 g Wool wax 5.00 g White petrolatum to 100 g Production takes place in analogy to Example 5.
Example 7 Roflumilast 0.10 g Neutral oil (Miglyol 812 ) 16.00 g Glycerol monostearate 8.00 g Cremophor A6 (BASF) 2.00 g Polyethylene glycol 400 62.50 g Purified water to 100.00 g Production takes place in analogy to Example 4.
Example 8 Roflumilast 0.10 g Neutral oil ( Miglyol 812 ) 16.00 g Glycerol monostearate 8.00 g Cremophor A6 (BASF) 4.00 g Polyethylene glycol 400 62.50 g Purified water to 100.00 g Production takes place in analogy to Example 4.
Example 9 Composition of an eye ointment (quantity for 1 000 grams) Roflumilast 1 g Cetyl alcohol 4 g High-viscosity paraffin 200 g White petrolatum 795 g WO 03/099334 - .10- PCT/EP03/05524 Production: A clear melt of the cetyl alcohol, the high-viscosity paraffin and the white petrolatum is pre-pared at about 70 C. The micronized roflumilast (90% of the particles below 10 pm) is stirred in, and a homogeneous dispersion is prepared using an Ultra-Turrax. The suspension is cooled to room tem-perature while stirring and used to fill suitable tubes.
Example 10 Composition of a drop solution in the form of an emulsion (quantity for 1 000 millilitres) Roflumilast 1.5 g Medium chain length triglycerides 100.0 g Lecithin 12.0 g Glycerol 25.0 g Thiomersal 0.1 g Purified water to 1 000 ml Production: First the roflumilast and then the lecithin are dissolved in the medium chain length triglyc-erides and the glycerol at 30 C-40 C. While stirring vigorously, the purified water is added and then homogenized until the droplet size of the disperse phase is below 500 nm. The thiomersal is dissolved by stirring. The emulsion is filtered through a 0.45 pm filter and dispensed into suitable containers.
Example 11 Composition of a nose ointment (quantity for 1 000 grams) Roflumilast 1 g Cetyl alcohol 4 g Wool wax 50 g High-viscosity paraffin 200 g White petrolatum 745 g Production: A clear melt of the cetyl alcohol, the high-viscosity paraffin, the wool wax and the white petrolatum is prepared at about 70 C. The micronized roflumilast (90% of the particles below 10pm) is stirred in, and a homogeneous dispersion is prepared using an Ultra-Turrax.
The suspension is cooled to room temperature while stirring and used to fill suitable tubes.
Investigations of the pharmacokinetics of the topical pharmaceutical preparations Comparison of pharmacokinetics parameters of topical pharmaceutical preparations of the in-vention with oral form Example A
A preparation corresponding to Example 7 and a preparation corresponding to Example 8 containing [14C]roflumilast were applied to shaven areas of rat skin (5 male Wistar rats) 4 cm2 in size. The radioac-tivity concentrations were measured in the plasma after I h, 4 h, 8 h, 24 h and in the urine (0-24 h) (n = 5). The dose was 1.7 mg/kg.
Results:
Preparation of Example 7: Cmax: 0.214 mg equiv./l, AUC(0-24 h): 4.13 (mg equiv./I x h) Preparation of Example 8: Cmax: 0.214 mg equiv./l, AUC(0-24 h): 3.99 (mg equiv./I x h) The results standardized to 1 mg/kg are Preparation of Example 7: Cmax: 0.126, AUC: 2.43 Preparation of Example 8: Cmax: 0.126, AUC: 2.35 Comparison with kinetic parameters after oral administration of 1 mg/kg:
Cmax: 0.225 mg equiv./l, AUC(0-24 h): 3.10 (mg equiv./I x h) The ratio of the AUC (preparation of Example 7) to the AUC (oral) is 78% and that of the AUG (prepara-tion of Example 8) to the AUG (oral) is 76%.
Results of comparison of the excretions with the urine:
Preparation of Example 7: 19.4% of the dose Preparation of Example 8: 18.0% of the dose Oral administration: 18.4% of the dose Conclusion:
After percutaneous administration of 1.7 mg/kg [14C]roflumilast to rats, the total radioactivity is trans-ported well through the skin and reaches a maximum plasma level of 0.214 mg equiv./I after 4 h, irre-spective of the preparation employed. Based on the total radioactivity, the AUCs and the excretions with the urine after percutaneous administration are negligibly different from those after oral administration.
- WO 03/099334 -12- PCT/EP03/05524 Example B
A preparation corresponding to Example 5 containing [14C]roflumilast was applied to a shaven area of rat skin (male Wistar rat) 4 cm2 in size. The radioactivity concentrations were measured in the plasma after 1 h, 4 h, 8 h, 24 h and in the urine (0-24 h) (n = 5). The dose was 1.77 mg/kg.
Preparation of Example 5: Cmax: 0.331 mg equiv./l, AUC(0-24 h): 4.99 (mg equiv./I x h) The results standardized to 1 mg/kg are Preparation of Example 5: Cmax: 0.187, AUC: 2.82 Comparison with kinetic parameters after oral administration of 1 mg/kg:
Cmax: 0.225 mg equiv./l, AUC(0-24 h): 3.10 (mg equiv./I x h) Results of comparison of the excretions with the urine:
Preparation of Example 5: 22.0% of the. dose Oral administration: 18.4% of the dose Conclusion:
These data show that roflumilast is absorbed from the preparation of Example 5 even somewhat better than from the preparations corresponding to Example 7 or 8. The excretion with the urine in the 24 h after administration is 22%, which is also in the region of the excretion with the urine after dermal ad-ministration of the preparations corresponding to Example 7 or 8. Comparison with oral administration shows that, irrespective of the composition of the topical preparation, similar Cmax and AUCs and simi-lar excretions with the urine are achieved.
WO 03/099334 -13- PCT/EP03/05524 Industrial applicability The dosage forms of the invention can be employed for the treatment and prevention of all diseases regarded as treatable or preventable through the use of PDE 4 inhibitors.
Selective cyclic nucleotide phosphodiesterase (PDE) inhibitors (specifically of type 4) are suitable on the one hand as bronchial therapeutic agents (for the treatment of airway obstructions owing to their dilating effect but also owing to their effect increasing the respiratory rate and respiratory drive) and for eliminating erectile dysfunc-tion owing to the vasodilating effect, but on the other hand especially for the treatment of disorders, especially of an inflammatory nature, e.g. of the airways (asthma prophylaxis), of the skin, of the central nervous system, of the intestine, of the eyes and of the joints, which are promoted by mediators such as histamine, PAF (platelet-activating factor), arachidonic acid derivatives such as leukotrienes and prostaglandins, cytokines, interleukins, chemokines, alpha-, beta- and gamma-interferon, tumor necro-sis factor (TNF) or oxygen free radicals and proteases. The pharmaceutical preparations of the inven-tion can therefore be used in human and veterinary medicine for example for the treatment and prophy-laxis of the following diseases: acute and chronic (especially inflammatory and allergen-induced) airway disorders of various aetiologies (bronchitis, allergic bronchitis, bronchial asthma, COPD); dermatoses (especially of a proliferative, inflammatory and allergic nature) such as, for example, psoriasis (vul-garis), toxic and allergic contact eczema, atopic eczema, seborrhoeic eczema, lichen simplex, sunburn, pruritus in the genitoanal region, alopecia areata, hypertrophic scars, discoid lupus erythematosus, follicular and extensive pyodermas, endogenous and exogenous acne, acne rosacea and other prolif-erative, inflammatory and allergic skin disorders; disorders based on excessive release of TNF and leukotrienes, e.g. disorders of the arthritic type (rheumatoid arthritis, rheumatoid spondylitis, osteoarthri-tis and other arthritic states), disorders of the immune system (AIDS, multiple sclerosis), types of shock [septic shock, endotoxin shock, gram-negative sepsis, toxic shock syndrome and ARDS (adult respira-tory distress syndrome)] and generalized inflammations in the gastrointestinal region (Crohn's disease and ulcerative colitis); disorders based on allergic and/or chronic abnormal immunological reactions in the region of the upper airways (pharyngeal space, nose) and adjacent regions (paranasal sinuses, eyes), such as, for example, allergic rhinitis/sinusitis, chronic rhinitis/sinusitis, allergic conjunctivitis, conjunctivitis caused by bacteria, viruses or fungi, inflammatory states after intraocular lens implanta-tion, inflammation of the optic nerve (neuritis nervi optici), keratitis, dry eye syndrome (keratitis sicca), uveitis, glaucoma, retinal oedema, retinitis pigmentosa, diabetic retinopathy, and nasal polyps; but also cardiac disorders which can be treated by PDE inhibitors, such as, for example, heart failure, or disor-ders which can be treated owing to the tissue-relaxant effect of PDE
inhibitors, such as, for example, erectile dysfunction or colic of the kidneys and ureters connected with kidney stones; or else disorders of the CNS such as, for example, depressions or arteriosclerotic dementia.
The pharmaceutical preparations of the invention are particularly suitable for the treatment of disorders of the skin such as dermatoses (especially of a proliferative, inflammatory and allergic nature) such as, for example, psoriasis (vulgaris), toxic and allergic contact eczema, atopic eczema, seborrhoeic ec-zema, lichen simplex, sunburn, pruritus in the genitoanal region, alopecia areata, hypertrophic scars, WO 03/099334 -14- PCT/EP03/05524 discoid lupus erythematosus, follicular and extensive pyodermas, endogenous and exogenous acne, acne rosacea and other proliferative, inflammatory and allergic skin disorders. Mention may preferably be made of the use of the pharmaceutical preparations of the invention in the treatment of psoriasis and atopic eczema.
The invention therefore also relates further to the use of roflumilast, salts of roflumilast, the N-oxide of roflumilast or salts thereof for producing a topical pharmaceutical preparation for dermal administration for the treatment of disorders of the skin which are regarded as treatable or preventable by application of PDE 4 inhibitors. Mention may preferably be made in this connection of dermatoses (especially of a proliferative, inflammatory and allergic nature) such as, for example, psoriasis (vulgaris), toxic and al-lergic contact eczema, atopic eczema, seborrhoeic eczema, lichen simplex, sunburn, pruritus in the genitoanal region, alopecia areata, hypertrophic scars, discoid lupus erythematosus, follicular and ex-tensive pyodermas, endogenous and exogenous acne, acne rosacea and other proliferative, inflamma-tory and allergic skin disorders.
The invention further relates to a method for the treatment of mammals, including humans, suffering from one of the abovementioned diseases. The method is characterized in that a therapeutically effec-tive and pharmacologically suitable amount of an active pharmaceutical ingredient selected from the group of compounds roflumilast, salts of roflumilast, the N-oxide of roflumilast and salts thereof is ad-ministered to the mammal with the disease, with the active pharmaceutical ingredient being adminis-tered in a topical pharmaceutical preparation of the invention. The disease is preferably a disorder of the skin such as dermatoses (especially of a proliferative, inflammatory and allergic nature) such as, for example, psoriasis (vulgaris), toxic and allergic contact eczema, atopic eczema, seborrhoeic eczema, lichen simplex, sunburn, pruritus in the genitoanal region, alopecia areata, hypertrophic scars, discoid lupus erythematosus, follicular and extensive pyodermas, endogenous and exogenous acne, acne rosacea and other proliferative, inflammatory and allergic skin disorders. The method is characterized in that the administration takes place by dermal administration, i.e. through application of the topical pharmaceutical preparations of the invention to the skin or mucous membranes.
In another preferred embodiment, the invention relates to the treatment of mammals, including humans, suffering from an eye disorder which is regarded as treatable or preventable through the use of PDE4 inhibitors. This eye disorder is preferably selected from the group of allergic conjunctivitis, conjunctivitis caused by bacteria, viruses or fungi, inflammatory states after intraocular lens implantation, inflamma-tion of the optic nerve (neuritis nervi optici), keratitis, dry eye syndrome (keratitis sicca), uveitis, glau-coma, retinal oedema, retinitis pigmentosa and diabetic retinopathy. The eye disorder is preferably al-lergic conjunctivitis, conjunctivitis caused by bacteria, viruses or fungi, inflammatory states after in-traocular lens implantation or uveitis. The method is characterized in that the administration takes place by application of the preparation of the invention to the eye.
The good systemic availability surprisingly observed on topical administration makes the pharmaceuti-WO 03/099334 -15- PCT/EP03/05524 cal preparations of the invention additionally suitable for systemic treatment and thus for the treatment of all other diseases which are regarded as treatable or preventable through application of PDE 4 inhibi-tors, especially the abovementioned diseases.
The invention therefore also relates further to the use of roflumilast, salts of roflumilast, the N-oxide of roflumilast or salts thereof for producing a topical pharmaceutical preparation for dermal administration for the systemic treatment of diseases regarded as treatable or preventable by application of PDE 4 inhibitors. Mention may preferably be made in this connection of acute and chronic (especially inflam-matory and allergen-induced) airway disorders of various aetiologies (bronchitis, allergic bronchitis, bronchial asthma, COPD), and disorders of the arthritic type (rheumatoid arthritis, rheumatoid spondy-litis, osteoarthritis and other arthritic states).
The pharmaceutical preparations of the invention are moreover particularly suitable for adminstration to groups of patients who are suffering from the abovementioned diseases and have problems in taking pharmaceutical preparations to be administered orally, such as, for example, bedridden patients, pa-tients in intensive medical care, patients with swallowing difficulties and children.
The invention further relates to a method for the treatment of mammals, including humans, suffering from one of the abovementioned diseases. The method is characterized in that a therapeutically effec-tive and pharmacologically suitable amount of an active pharmaceutical ingredient selected from the group of compounds roflumilast, salts of roflumilast, the N-oxide of roflumilast and salts thereof is ad-ministered to the mammal with the disease, with the active pharmaceutical ingredient being adminis-tered in a topical pharmaceutical preparation of the invention. The disease is preferably acute and chronic (especially inflammatory and allergen-induced) airway disorders of various aetiologies (bronchi-tis, allergic bronchitis, bronchial asthma, COPD), and disorders of the arthritic type (rheumatoid arthritis, rheumatoid spondylitis, osteoarthritis and other arthritic states). The method is characterized in that administration takes place by dermal administration, i.e. through application of the topical pharmaceuti-cal preparations of the invention to the skin or mucous membranes.
The dosage forms of the invention comprise the active pharmaceutical ingredient in the dose customary for the treatment of the particular disease. The dosage of the active ingredient is of the order of magni-tude customary for PDE inhibitors, it being possible to administer the daily dose in one or more dosage units. Customary dosages are disclosed for example in WO 95/01338. The normal dose on systemic therapy (oral) is between 0.001 and 3 mg per kilogram and day. Dosage forms preferred according to the invention for topical administration contain from 0.005 mg to 5 mg of roflumilast, preferably from 0.01 mg to 2.5 mg, particularly preferably 0.1 mg to 0.5 mg of roflumilast per dosage unit. Examples of pharmaceutical preparations of the invention contain 0.01 mg, 0.1 mg, 0.125 mg, 0.25 mg and 0.5 mg of roflumilast per dosage unit.
Claims (13)
1. Topically applicable pharmaceutical preparation for dermal administration for the treatment of dermatosis comprising an active pharmaceutical ingredient together with one or more pharmaceutical carriers and/or excipients suitable for topical administration, wherein the active pharmaceutical ingredient is a compound selected from the group consisting of roflumilast, salts of roflumilast, the N-oxide of the pyridine residue of roflumilast and salts of the N-oxide of the pyridine residue of roflumilast, and wherein one of the excipients is selected from the group of solid or liquid paraffins and polyalcohols.
wherein roflumilast is a compound of the formula I
in which R1 is difluoromethoxy, R2 is cyclopropylmethoxy, and R3 is 3,5-dichloropyrid-4-yl.
wherein roflumilast is a compound of the formula I
in which R1 is difluoromethoxy, R2 is cyclopropylmethoxy, and R3 is 3,5-dichloropyrid-4-yl.
2. Topically applicable pharmaceutical preparation according to claim 1, wherein the polyalcohol is selected from the group consisting of glycerol, sorbitol, propylene glycol and polyethylene glycols.
3. Topically applicable pharmaceutical preparation according to claim 2, wherein the polyalcohol is polyethylene glycol.
4. Topically applicable pharmaceutical preparation according to any one of claims 1-3, which is a semisolid dosage form selected from the group consisting of an ointment, a cream, a gel and a paste.
5. Topically applicable pharmaceutical preparation according to claim 4, wherein the ointment is a solution ointment.
6. Topically applicable pharmaceutical preparation according to claim 4, wherein the ointment is a suspension ointment.
7. Topically applicable pharmaceutical preparation according to any one of claims 1-3, which is a transdermal therapeutic system (TTS).
8. Topically applicable pharmaceutical preparation according to any one of claims 1-7, wherein the dermatosis is psoriasis, psoriasis vulgaris, toxic and allergic contact eczema, atopic eczema, seborrhoeic eczema, lichen simplex, sunburn, pruritus in the genitoanal region, alopecia areata, hypertrophic scars, discoid lupus erythematosus, follicular and extensive pyodermas, endogenous and exogenous acne, acne rosacea or other proliferative, inflammatory and allergic skin disorders.
9. Use of roflumilast, salts of roflumilast, the N-oxide of roflumilast or a salt of the N-oxide of roflumilast for producing a topically applicable pharmaceutical preparation for dermal administration for the systemic treatment of diseases, which are treatable or preventable through use of PDE 4 inhibitors, wherein roflumilast is a compound of the formula I
in which R1 is difluoromethoxy, R2 is cyclopropylmethoxy, and R3 is 3,5-dichloropyrid-4-yl.
in which R1 is difluoromethoxy, R2 is cyclopropylmethoxy, and R3 is 3,5-dichloropyrid-4-yl.
10. Use according to claim 9, wherein the disease is selected from acute and chronic airway disorders of various aetiologies or disorders of the arthritic type.
11. Use according to claim 10, wherein the acute and chronic airway disorders are inflammatory and allergen induced and wherein the acute and chronic airways disorders of various aetiologies are bronchitis, allergic, bronchitis, bronchial asthma and COPD.
12. Use according to claim 11, wherein the airway disorder is COPD.
13. Use according to claim 11, wherein the disorders of the arthritic type are rheumatoid arthritis, rheumatoid spondylitis, osteoarthritis and other arthritic states.
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE10223828.6 | 2002-05-28 | ||
| EP02011830 | 2002-05-28 | ||
| EP02011830.3 | 2002-05-28 | ||
| DE10223828 | 2002-05-28 | ||
| DE10311613 | 2003-03-14 | ||
| DE10311613.3 | 2003-03-14 | ||
| PCT/EP2003/005524 WO2003099334A1 (en) | 2002-05-28 | 2003-05-27 | Topically applicable pharmaceutical preparation |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2486917A1 CA2486917A1 (en) | 2003-12-04 |
| CA2486917C true CA2486917C (en) | 2011-11-22 |
Family
ID=29587313
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2486910A Expired - Fee Related CA2486910C (en) | 2002-05-28 | 2003-05-27 | Ophthalmological use of roflumilast for the treatment of diseases of the eye |
| CA2486917A Expired - Fee Related CA2486917C (en) | 2002-05-28 | 2003-05-27 | Topically applicable pharmaceutical preparation containing roflumilast |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2486910A Expired - Fee Related CA2486910C (en) | 2002-05-28 | 2003-05-27 | Ophthalmological use of roflumilast for the treatment of diseases of the eye |
Country Status (33)
| Country | Link |
|---|---|
| US (7) | US20060084684A1 (en) |
| EP (3) | EP1511516B1 (en) |
| JP (3) | JP2005529928A (en) |
| KR (2) | KR101307093B1 (en) |
| CN (3) | CN100490804C (en) |
| AT (2) | ATE417628T1 (en) |
| AU (2) | AU2003232828B2 (en) |
| BR (2) | BR0311339A (en) |
| CA (2) | CA2486910C (en) |
| CY (2) | CY1110312T1 (en) |
| DE (2) | DE60325354D1 (en) |
| DK (3) | DK2020243T3 (en) |
| EA (2) | EA010416B1 (en) |
| ES (3) | ES2693094T3 (en) |
| HK (2) | HK1079437A1 (en) |
| HR (1) | HRP20041211B1 (en) |
| HU (1) | HUE039709T2 (en) |
| IL (3) | IL164935A (en) |
| IS (1) | IS2639B (en) |
| LT (1) | LT2020243T (en) |
| MA (1) | MA27813A1 (en) |
| ME (1) | ME00565A (en) |
| MX (2) | MXPA04011528A (en) |
| NO (2) | NO334882B1 (en) |
| NZ (3) | NZ553731A (en) |
| PL (3) | PL397021A1 (en) |
| PT (3) | PT1511481E (en) |
| RS (1) | RS51104B (en) |
| SI (2) | SI2020243T1 (en) |
| TR (1) | TR201815573T4 (en) |
| UA (2) | UA81910C2 (en) |
| WO (2) | WO2003099278A1 (en) |
| ZA (2) | ZA200408649B (en) |
Families Citing this family (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6872382B1 (en) | 2001-05-21 | 2005-03-29 | Alcon, Inc. | Use of selective PDE IV inhibitors to treat dry eye disorders |
| MY140561A (en) | 2002-02-20 | 2009-12-31 | Nycomed Gmbh | Dosage form containing pde 4 inhibitor as active ingredient |
| DK2020243T3 (en) * | 2002-05-28 | 2018-11-19 | Astrazeneca Ab | Pharmaceutical composition which can be applied topically |
| CA2497977A1 (en) | 2002-09-20 | 2004-04-01 | Alcon, Inc. | Use of cytokine synthesis inhibitors for the treatment of dry eye disorders |
| FR2851247B1 (en) * | 2003-02-19 | 2007-06-29 | Exonhit Therapeutics Sa | METHODS AND COMPOSITIONS FOR THE TREATMENT OF OCULAR DEGENERATIVE PATHOLOGIES |
| EP1606261B1 (en) | 2003-03-10 | 2009-11-04 | Nycomed GmbH | Novel process for the preparation of roflumilast |
| JP2007517893A (en) * | 2004-01-10 | 2007-07-05 | バイオリピッド インコーポレイテッド | Lipid composition and method of using the lipid composition |
| DE102004046236A1 (en) * | 2004-09-22 | 2006-03-30 | Altana Pharma Ag | drug preparation |
| DE102004046235A1 (en) * | 2004-09-22 | 2006-03-30 | Altana Pharma Ag | drug preparation |
| CN102600144A (en) * | 2005-03-08 | 2012-07-25 | 奈科明有限责任公司 | Roflumilast for the treatment of diabetes mellitus |
| JP5383183B2 (en) * | 2005-03-16 | 2014-01-08 | タケダ ゲゼルシャフト ミット ベシュレンクテル ハフツング | A tasted dosage form containing roflumilast |
| WO2006132342A1 (en) * | 2005-06-09 | 2006-12-14 | Santen Pharmaceutical Co., Ltd. | Eye drop containing roflumilast |
| CA2637573C (en) | 2006-02-21 | 2013-07-02 | Eisai R&D Management Co., Ltd. | 4-(3-benzoylaminophenyl)-6,7-dimethoxy-2-methylaminoquinazoline derivatives |
| EP2123641A4 (en) | 2007-02-16 | 2011-06-22 | Eisai R&D Man Co Ltd | Crystal, amorphous form and salt of methyl n-ý3-(6,7-dimethoxy- 2-methylaminoquinazolin-4-yl)phenyl¨terephthalamic acid |
| WO2009025239A1 (en) | 2007-08-17 | 2009-02-26 | Eisai R & D Management Co., Ltd. | Novel preparation for external use |
| CN101687820B (en) | 2007-08-17 | 2012-07-25 | 卫材R&D管理有限公司 | Method for producing quinazoline derivative |
| AU2010318687B2 (en) | 2009-10-30 | 2016-02-25 | Nestec S.A. | Methods for maintaining eye health and ameliorating opthalmic maladies in canines |
| ES2408132B1 (en) * | 2010-09-08 | 2014-04-04 | Universidad Miguel Hernández De Elche | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF THE EPIPHORE. |
| ES2377785B2 (en) * | 2010-09-08 | 2012-09-26 | Universidad Miguel Hernández De Elche | PHARMACEUTICAL COMPOSITION FOR DRY EYE TREATMENT. |
| WO2012121988A2 (en) * | 2011-03-07 | 2012-09-13 | Celgene Corporation | Methods for treating diseases using isoindoline compounds |
| CN102793684B (en) * | 2011-05-26 | 2016-02-17 | 杭州赛利药物研究所有限公司 | Roflumilast liquid preparation and preparation method thereof |
| MX2013015287A (en) * | 2011-06-28 | 2014-03-31 | Bayer Healthcare Llc | Topical ophthalmological pharmaceutical composition containing regorafenib. |
| WO2013155123A1 (en) * | 2012-04-10 | 2013-10-17 | Georgia State University Research Foundation, Inc. | Compositions and methods for treating otitis media and other conditions with inhibitors of cyld |
| WO2014012954A1 (en) | 2012-07-18 | 2014-01-23 | Takeda Gmbh | Treatment of partly controlled or uncontrolled severe asthma |
| CN103570610B (en) * | 2012-07-18 | 2017-08-11 | 重庆华邦制药有限公司 | A kind of preparation method of roflumilast particle |
| KR20150079745A (en) * | 2012-11-08 | 2015-07-08 | 리젠 파마슈티컬스 소시에떼 아노님 | Pharmaceutical compositions containing a pde4 inhibitor and a pi3 delta or dual pi3 delta-gamma kinase inhibitor |
| ES2888074T3 (en) | 2013-08-16 | 2021-12-30 | Univ Maastricht | Treatment of cognitive impairment with PDE4 inhibitor |
| CN105434328A (en) * | 2014-09-01 | 2016-03-30 | 天津药物研究院有限公司 | Roflumilast solid dispersion-containing solid preparation and preparation method thereof |
| KR101878621B1 (en) * | 2014-10-24 | 2018-07-13 | 히사미쓰 세이야꾸 가부시키가이샤 | Prodrug |
| CN104997959A (en) * | 2015-08-21 | 2015-10-28 | 蔡宇平 | Traditional Chinese medicine for treating chalazion |
| CN106148528B (en) * | 2016-07-11 | 2019-10-01 | 赵晨 | A kind of pathogenic mutation and its detection reagent of heredity Usher syndrome |
| US11129818B2 (en) | 2017-06-07 | 2021-09-28 | Arcutis Biotherapeutics, Inc. | Topical roflumilast formulation having improved delivery and plasma half life |
| US9895359B1 (en) | 2017-06-07 | 2018-02-20 | Arcutis, Inc. | Inhibition of crystal growth of roflumilast |
| US11534493B2 (en) | 2017-09-22 | 2022-12-27 | Arcutis Biotherapeutics, Inc. | Pharmaceutical compositions of roflumilast in aqueous blends of water-miscible, pharmaceutically acceptable solvents |
| CN108283620A (en) * | 2018-03-13 | 2018-07-17 | 兆科药业（广州）有限公司 | A kind of local medicine composition of inhibitors of phosphodiesterase-4 and preparation method thereof |
| KR20210044191A (en) * | 2018-06-04 | 2021-04-22 | 아큐티스, 인크. | Roflumilast skin penetration delay time improvement method and formulation |
| KR102117525B1 (en) * | 2018-07-09 | 2020-06-01 | 건양대학교 산학협력단 | Pharmaceutical Composition for Preventing or Treating Chronic Rhinosinusitis Comprising PDE4B Inhibitor |
| US20200155524A1 (en) * | 2018-11-16 | 2020-05-21 | Arcutis, Inc. | Method for reducing side effects from administration of phosphodiesterase-4 inhibitors |
| BR112022015104A2 (en) | 2020-01-31 | 2022-09-27 | Arcutis Biotherapeutics Inc | METHOD TO IMPROVE THE DISTRIBUTION AND EXTEND THE PLASMATIC HALF-LIFE OF A ROFLUMILAST COMPOSITION AND USE OF A COMPOSITION |
| BR112022007459A2 (en) * | 2020-05-07 | 2022-11-29 | Arcutis Biotherapeutics Inc | METHOD FOR TREATMENT OF AN EPIDERMAL BARRIER WITH DECREASE FUNCTION, PHARMACEUTICAL COMPOSITION, COMPOSITION AND METHOD FOR REDUCING EPIDERMAL LIPID EXTRACTION AND ENHANCEMENT OF EPIDERMAL BARRIER FUNCTION |
| WO2022169615A1 (en) | 2021-02-05 | 2022-08-11 | Arcutis Biotherapeutics, Inc. | Roflumilast formulations with an improved pharmacokinetic profile |
| EP4291162A1 (en) * | 2021-02-10 | 2023-12-20 | Iolyx Therapeutics, Inc. | Methods for ophthalmic delivery of roflumilast |
| CN116867480A (en) * | 2021-02-10 | 2023-10-10 | 洛利克斯治疗有限公司 | Methods of ocular delivery of roflumilast |
| EP4351612A2 (en) * | 2021-06-01 | 2024-04-17 | Eyedea Bio, Llc | Extended release drug delivery system for ocular drugs and methods of use |
| WO2023049809A1 (en) * | 2021-09-22 | 2023-03-30 | Iolyx Therapeutics, Inc. | Methods of treating ocular inflammatory diseases |
| US20240108609A1 (en) | 2022-09-15 | 2024-04-04 | Arcutis Biotherapeutics, Inc. | Pharmaceutical compositions of roflumilast and solvents capable of dissolving high amounts of the drug |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4753945A (en) * | 1986-02-19 | 1988-06-28 | Eye Research Institute Of Retina Foundation | Stimulation of tear secretion with phosphodiesterase inhibitors |
| US5011843A (en) * | 1988-05-31 | 1991-04-30 | Iolab Corporation | Treatment of glaucoma using phosphodiesterase inhibitors |
| US5891904A (en) * | 1992-09-14 | 1999-04-06 | Wolf-Georg Forssmann | Use of inhibitors of phosphodiesterase IV |
| CA2165192C (en) * | 1993-07-02 | 2001-04-24 | Hermann Amschler | Fluoroalkoxy-substituted benzamides and their use as cyclic nucleotide phosphodiesterase inhibitors |
| CN1128955A (en) * | 1993-08-10 | 1996-08-14 | 藤泽药品工业株式会社 | Percutaneously absorbable prepn. |
| ZA954599B (en) * | 1994-06-07 | 1996-01-26 | Allergan Inc | Stable gel formulation for topical treatment of skin conditions |
| EP1118615A4 (en) * | 1998-09-29 | 2002-02-27 | Fujisawa Pharmaceutical Co | Novel salts of pyridopyrazine compound and crystals thereof |
| US6395746B1 (en) * | 1998-09-30 | 2002-05-28 | Alcon Manufacturing, Ltd. | Methods of treating ophthalmic, otic and nasal infections and attendant inflammation |
| US20020006418A1 (en) * | 1998-10-13 | 2002-01-17 | John Kung | Composition to enhance permeation of topical skin agents |
| AU3284000A (en) | 1999-03-10 | 2000-09-28 | Byk Gulden Lomberg Chemische Fabrik Gmbh | 3-cyclopropylmethoxy-4-difluoromethoxy-n-(3,5-dichloropyrid- 4-yl)benzamide in the treatment of multiple sclerosis |
| US6174878B1 (en) * | 1999-08-31 | 2001-01-16 | Alcon Laboratories, Inc. | Topical use of kappa opioid agonists to treat otic pain |
| KR20020050249A (en) * | 1999-10-29 | 2002-06-26 | 스튜어트 알. 수터, 스티븐 베네티아너, 피터 존 기딩스 | Method for administering a phosphodiesterase 4 inhibitor |
| AP2002002590A0 (en) * | 2000-01-31 | 2002-09-30 | Pfizer Prod Inc | Pyrimidinyl carboxamides useful as inhibitors of PDE4 isozymes. |
| WO2001060358A1 (en) * | 2000-02-16 | 2001-08-23 | University Of Nebraska Medical Center | Method and compositions for treating fibrotic diseases |
| JP2003534328A (en) * | 2000-05-25 | 2003-11-18 | メルク フロスト カナダ アンド カンパニー | Fluoroalkoxy-substituted benzamide dichloropyridinyl N-oxide PDE4 inhibitors |
| AU2002227123A1 (en) * | 2000-11-07 | 2002-05-21 | Merck And Co., Inc. | Method of treatment with a combination of a pde4 inhibitor and a leukotriene antagonist |
| UA77656C2 (en) * | 2001-04-07 | 2007-01-15 | Glaxo Group Ltd | S-fluoromethyl ester of 6-alpha, 9-alpha-difluoro-17-alpha-[(2-furanylcarbonyl)oxy]-11-beta-hydroxy-16- alpha-methyl-3-oxoandrosta-1,4-dien-17-beta-carbothioacid as anti-inflammatory agent |
| US6872382B1 (en) * | 2001-05-21 | 2005-03-29 | Alcon, Inc. | Use of selective PDE IV inhibitors to treat dry eye disorders |
| US20030092706A1 (en) * | 2001-11-09 | 2003-05-15 | Johannes Barsig | Combination |
| DK2020243T3 (en) * | 2002-05-28 | 2018-11-19 | Astrazeneca Ab | Pharmaceutical composition which can be applied topically |
-
2003
- 2003-05-27 DK DK08166780.0T patent/DK2020243T3/en active
- 2003-05-27 TR TR2018/15573T patent/TR201815573T4/en unknown
- 2003-05-27 JP JP2004506802A patent/JP2005529928A/en active Pending
- 2003-05-27 BR BR0311339-6A patent/BR0311339A/en not_active Application Discontinuation
- 2003-05-27 AU AU2003232828A patent/AU2003232828B2/en not_active Ceased
- 2003-05-27 CN CNB038120941A patent/CN100490804C/en not_active Expired - Fee Related
- 2003-05-27 KR KR1020117025130A patent/KR101307093B1/en not_active IP Right Cessation
- 2003-05-27 EP EP03755048A patent/EP1511516B1/en not_active Expired - Lifetime
- 2003-05-27 PT PT03730122T patent/PT1511481E/en unknown
- 2003-05-27 UA UA20041210683A patent/UA81910C2/en unknown
- 2003-05-27 NZ NZ553731A patent/NZ553731A/en not_active IP Right Cessation
- 2003-05-27 ME MEP-854/08A patent/ME00565A/en unknown
- 2003-05-27 EA EA200401517A patent/EA010416B1/en not_active IP Right Cessation
- 2003-05-27 WO PCT/EP2003/005536 patent/WO2003099278A1/en active Application Filing
- 2003-05-27 CA CA2486910A patent/CA2486910C/en not_active Expired - Fee Related
- 2003-05-27 EP EP03730122A patent/EP1511481B1/en not_active Expired - Lifetime
- 2003-05-27 EP EP08166780.0A patent/EP2020243B1/en not_active Expired - Lifetime
- 2003-05-27 PT PT08166780T patent/PT2020243T/en unknown
- 2003-05-27 NZ NZ536920A patent/NZ536920A/en not_active IP Right Cessation
- 2003-05-27 DK DK03730122.3T patent/DK1511481T3/en active
- 2003-05-27 DK DK03755048T patent/DK1511516T3/en active
- 2003-05-27 HU HUE08166780A patent/HUE039709T2/en unknown
- 2003-05-27 SI SI200332580T patent/SI2020243T1/en unknown
- 2003-05-27 ES ES08166780.0T patent/ES2693094T3/en not_active Expired - Lifetime
- 2003-05-27 ES ES03730122T patent/ES2354971T3/en not_active Expired - Lifetime
- 2003-05-27 AT AT03755048T patent/ATE417628T1/en active
- 2003-05-27 CN CN038124068A patent/CN1655823B/en not_active Expired - Fee Related
- 2003-05-27 KR KR10-2004-7019272A patent/KR20050014844A/en not_active Application Discontinuation
- 2003-05-27 DE DE60325354T patent/DE60325354D1/en not_active Expired - Lifetime
- 2003-05-27 MX MXPA04011528A patent/MXPA04011528A/en active IP Right Grant
- 2003-05-27 US US10/515,698 patent/US20060084684A1/en not_active Abandoned
- 2003-05-27 CN CN2009100043805A patent/CN101491520B/en not_active Expired - Fee Related
- 2003-05-27 ES ES03755048T patent/ES2319517T3/en not_active Expired - Lifetime
- 2003-05-27 CA CA2486917A patent/CA2486917C/en not_active Expired - Fee Related
- 2003-05-27 WO PCT/EP2003/005524 patent/WO2003099334A1/en active Application Filing
- 2003-05-27 EA EA200702588A patent/EA020569B1/en not_active IP Right Cessation
- 2003-05-27 AU AU2003240719A patent/AU2003240719B2/en not_active Ceased
- 2003-05-27 NZ NZ537308A patent/NZ537308A/en not_active IP Right Cessation
- 2003-05-27 RS YUP-1014/04A patent/RS51104B/en unknown
- 2003-05-27 UA UAA200712909A patent/UA88523C2/en unknown
- 2003-05-27 SI SI200331532T patent/SI1511516T1/en unknown
- 2003-05-27 PT PT03755048T patent/PT1511516E/en unknown
- 2003-05-27 MX MXPA04011612A patent/MXPA04011612A/en active IP Right Grant
- 2003-05-27 PL PL397021A patent/PL397021A1/en unknown
- 2003-05-27 PL PL372082A patent/PL211870B1/en unknown
- 2003-05-27 PL PL372095A patent/PL212134B1/en unknown
- 2003-05-27 US US10/515,896 patent/US20060084685A1/en not_active Abandoned
- 2003-05-27 DE DE60334692T patent/DE60334692D1/en not_active Expired - Lifetime
- 2003-05-27 BR BR0311337-0A patent/BR0311337A/en not_active Application Discontinuation
- 2003-05-27 AT AT03730122T patent/ATE485821T1/en active
- 2003-05-27 LT LTEP08166780.0T patent/LT2020243T/en unknown
- 2003-05-27 JP JP2004506857A patent/JP5652983B2/en not_active Expired - Lifetime
-
2004
- 2004-10-21 MA MA27912A patent/MA27813A1/en unknown
- 2004-10-26 ZA ZA200408649A patent/ZA200408649B/en unknown
- 2004-10-31 IL IL164935A patent/IL164935A/en not_active IP Right Cessation
- 2004-11-07 IL IL165065A patent/IL165065A/en active IP Right Grant
- 2004-11-26 ZA ZA200409584A patent/ZA200409584B/en unknown
- 2004-12-16 NO NO20045506A patent/NO334882B1/en not_active IP Right Cessation
- 2004-12-23 IS IS7612A patent/IS2639B/en unknown
- 2004-12-27 HR HRP20041211AA patent/HRP20041211B1/en not_active IP Right Cessation
- 2004-12-27 NO NO20045656A patent/NO334916B1/en not_active IP Right Cessation
-
2005
- 2005-12-14 HK HK05111481.8A patent/HK1079437A1/en not_active IP Right Cessation
- 2005-12-16 HK HK05111628.2A patent/HK1079445A1/en not_active IP Right Cessation
-
2008
- 2008-04-29 US US12/149,250 patent/US20080280958A1/en not_active Abandoned
-
2009
- 2009-03-10 CY CY20091100273T patent/CY1110312T1/en unknown
-
2010
- 2010-11-30 IL IL209657A patent/IL209657A0/en unknown
-
2011
- 2011-08-26 US US13/219,056 patent/US20110313005A1/en not_active Abandoned
-
2012
- 2012-07-09 JP JP2012154020A patent/JP5683538B2/en not_active Expired - Lifetime
-
2013
- 2013-11-08 US US14/075,035 patent/US20140303215A1/en not_active Abandoned
-
2018
- 2018-10-03 US US16/150,759 patent/US20190029956A1/en not_active Abandoned
- 2018-10-24 CY CY181101093T patent/CY1121133T1/en unknown
-
2020
- 2020-06-03 US US16/891,823 patent/US20210116207A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2486917C (en) | Topically applicable pharmaceutical preparation containing roflumilast | |
| EP2214644B1 (en) | Water-immiscible materials as vehicles for drug delivery | |
| EP1754491A1 (en) | Ophthalmic percutaneously absorbed preparation containing muscarinic receptor agonist | |
| WO2010041684A1 (en) | Tacrolimus preparation for external applications | |
| JP3410364B2 (en) | Difluprednate-containing composition | |
| WO2005053672A1 (en) | Remedy for pruritus comprising cilomilast or salt thereof as the active ingredient | |
| MXPA00006079A (en) | Topical carbamazepine formulations and methods of use |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| MKLA | Lapsed |
Effective date: 20170529 |